Please use the links at the top of the page to navigate through our site.

2022 Update
Association of Police Controlled Drug Liaison Officers

We have received a number of enquiries from companies / applicants who intend to apply to the Home Office for a licence in respect of the below Governments Response to the report by the Advisory Council on the Misuse of Drugs (ACMD) legislation which came into effect on 15.6.22.

Government’s response  

The ACMD’s report “An assessment of the harms of gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and closely related compounds”.

I am mindful of the ACMD’s advice that the recommendations be considered as a single package, and of the Council’s concern to avoid unintended consequences. However, I also agree that action is needed to implement the legislative recommendations that will tighten the law on these substances, and I therefore agree to Recommendation 3 (that GHB, GBL and 1,4-butanediol (1,4-BD) be moved from Class C to Class B of the Misuse of Drugs Act 1971) and Recommendation 4 (that GBL and 1,4-BD are placed under Schedule 1 of the Misuse of Drugs Regulations 2001, so that industrial users will require a controlled drug licence). It is my view that we should begin the process of amending the legislation to implement Recommendations 3 and 4, subject to Parliamentary approval, as soon as possible.

If you are a business seeking a controlled drug licence, it may help ypur application to visit the below which should answer most of the questions you may have.


If further advice is required, our association suggests you contact

rather than the APCDLO.